Skip to main navigation
Barinthus Biotherapeutics logo
Top Navigation
  • Home
  • About Us
    • Overview
    • Our Team
    • A Name with Purpose
  • Technology
    • Overview
    • Viral Vector Platforms
    • Synthetic Platforms
  • Pipeline
    • Overview
    • Infectious Diseases
    • Autoimmunity
    • Cancer
  • Partnerships
    • Overview
    • Infectious Diseases
    • Autoimmunity
    • Cancer
  • Investors
    • Overview
    • News & Filings
    • Events & Presentations
    • Stock Information
    • Corporate Governance
    • Investor FAQs
    • Contact IR
  • Careers
    • Overview
    • Working Here
    • Diversity & Inclusion
    • Our Values
    • Recruitment Companies
  • Contact
    • Overview
    • Patient Enquiries
Select Page

Annual Reports and AGM

Toolkit
  • Subscribe
  • RSS Feeds
  • Contact IR
  • Presentations
Sub Nav News & Filings
Press Releases
SEC Filings
Annual Reports and AGM
Quarterly Results
Annual Reports and AGM
Show all

Annual Reports

2024/2025

  • Form 10-K
  • Annual Report and Accounts for the Year Ended 31 December 2024 3.9 MB
  • Form of UK proxy card 2025 142.9 KB
  • Notice of Barinthus Biotherapeutics plc Annual General Meeting 2025 179.8 KB
  • Proxy Statement 938.5 KB
  • Poll Voting Results of the 2025 AGM 122.6 KB

Annual Reports

2023/2024

  • Form 10-K
  • Annual Report and Accounts for the Year Ended 31 December 2023 4.2 MB
  • Form of UK proxy card 2024 143.1 KB
  • Notice of Barinthus Biotherapeutics plc Annual General Meeting 2024 138 KB
  • Proxy Statement 936.2 KB
  • Poll Voting Results of the 2024 AGM 83.3 KB

Annual Reports

2022/2023

  • Form 10-K
  • Proxy statement May 2023 4.3 MB
  • Annual Report and Accounts for the Year Ended 31 December 2022 3.8 MB
  • Notice of Vaccitech plc Annual General Meeting May 2023 653.6 KB
  • Form of UK Proxy Card May 2023 606.3 KB
  • Poll Voting Results of the May 2023 AGM 193.9 KB
  • Form of UK Proxy Card - General Meeting, November 41.9 KB
  • Proxy Statement - General Meeting, November 371.4 KB
  • UK General Meeting Notice, November 179.8 KB

Annual Reports

2021/2022

  • Form 10-K
  • Proxy statement 2.5 MB
  • Annual Report and Accounts for the Year Ended 31 December 2021 4.1 MB
  • Notice of Vaccitech plc Annual General Meeting 2022 410.4 KB
  • Form of UK Proxy Card 2022 510.2 KB

Barinthus Biotherapeutics plc

Unit 6-10
Zeus Building
Rutherford Avenue
Harwell OX11 0DF
United Kingdom

T: +44 (0)1865 818808

Footer Links
Home
About
Sitemap
Privacy Policy
Privacy Notice
Careers
Contact
Barinthus Biotherapeutics logo
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer.
© Barinthus Biotherapeutics 2026 All rights reserved.
Social Media Links
  • Follow us on X
  • Follow us on LinkedIn